相关实验视频
Updated: Apr 12, 2026
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
1.9K
使用塞拉斯特治疗肥胖症
Junli Liu1, Jaemin Lee1, Mario Andres Salazar Hernandez1
1Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02130, USA.
Cell
|May 23, 2015
概括
塞拉斯特是一种天然化合物,通过增强瘦素敏感性,显示出作为抗肥胖药物的前景. 这种药物有效地降低了肥胖小鼠的体重,为肥胖治疗提供了新的治疗途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
- 自然产品 自然产品
背景情况:
- 肥胖仍然是一个重大的全球健康挑战,有效的药理疗法有限.
- 瘦素是体重调节中的关键激素,已经显示出治疗潜力,但瘦素耐药性是一个主要障碍.
- 现有的治疗方法往往由于勒素耐药性等问题而失败.
研究的目的:
- 使用in silico药物查来识别新的抗肥胖药物.
- 研究塞拉斯特作为潜在的肥胖治疗的疗效和机制.
- 在肥胖的临床前模型中评估塞拉斯特的有效性.
主要方法:
- 使用in silico药物选来识别潜在的治疗化合物.
- 来自Tripterygium Wilfordi的天然产品塞拉斯特罗尔被选中进行进一步研究.
- 塞拉斯特的抗肥胖作用在饮食诱导的肥胖 (DIO),缺素 (ob/ob) 和缺素受体 (db/db) 的小鼠模型中进行了评估.
主要成果:
- 塞拉斯特显示出显著的抗肥胖作用,包括抑制食物摄入量和保持能量消耗.
- 在用塞拉斯特罗尔治疗的高勒普提内米性DIO小鼠中观察到高达45%的体重减轻.
- 塞拉斯托尔在缺乏叶黄素 (ob/ob) 和缺乏叶黄素受体 (db/db) 的小鼠中无效,这表明依赖于叶黄素信号的机制.
结论:
- 塞拉斯托尔作为一个瘦素敏感剂,增强身体对瘦素的反应.
- 这些发现突出了塞拉斯特作为药理肥胖治疗的有希望的候选人.
- 塞拉斯托尔可能为肥胖提供一种新的治疗策略,特别是在涉及勒素耐药性的情况下.
相关概念视频
01:24Obesity
1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
01:21Drug Dosing: Obese Patients
346
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
346
01:21Drugs for Treatment of Constipation-Predominant IBS
1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
303
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
303
01:26Atherosclerosis III: Management
602
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
901
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
901